How Has the Cardiac Marker Testing Market Size Evolved in Recent Years?
The cardiac marker testing market has seen considerable growth due to a variety of factors.
• The swift expansion of the cardiac marker testing market in the latest years is remarkable. The market is expected to surge from $6.52 billion in 2024 to $7.19 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%.
Factors such as the escalating elderly population, heightened educational drives, increased awareness, developed healthcare infrastructure, and a climbing patient population have contributed to the historic period's growth.
What Are The Predictions for The Cardiac Marker Testing Market in the Coming Years?
The cardiac marker testing market is expected to maintain its strong growth trajectory in upcoming years.
• The market for cardiac marker testing is projected to experience swift expansion in the coming years, reaching a value of $10.56 billion by 2029 with a compound annual growth rate (CAGR) of 10.1%.
Factors contributing to the growth during this forecast period include a rise in cardiovascular disease cases, an upswing in strategic collaborations and partnerships, an increase in research and development endeavors, positive reimbursement policies, and a surge in demand for point-of-care (POC) testing. Noteworthy trends for this prediction period encompass enhanced diagnostic technologies, automated analyzers, sophisticated cardiac marker testing assays, digital health tech advancements, and the unveiling of integrative technologies.
Which Drivers Are Accelerating Growth In The Cardiac Marker Testing Market?
The cardiac marker testing market is set to expand, spurred by the escalating prevalence of cardiovascular diseases. Comprising a variety of disorders that implicate the heart and blood vessels, cardiovascular diseases include ailments like coronary artery disease, heart failure, and stroke. An unhealthy diet, sedentary lifestyle, tobacco and harmful alcohol consumption, and air pollution contribute to the increase in these diseases. The need for cardiac marker tests to accurately diagnose and assess the severity of heart conditions, as well as monitor the progression or treatment response, is paramount. These tests detect specific biomarkers released during myocardial injury. The American Heart Association reported in January 2024 that the age-adjusted death rate from cardiovascular disease rose 4.0% to 233.3 per 100,000, up from 224.4 per 100,000 in the previous year. Furthermore, sudden cardiac arrest caused 20,114 deaths in the U.S. in 2021. This growing prevalence of cardiovascular diseases underscores the expansion of the cardiac marker testing market.
What Are The Core Segments Of The Global Cardiac Marker Testing Market?
The cardiac marker testingmarket covered in this report is segmented –
1) By Product: Reagents And Kits, Instruments
2) By Biomarker Type: Troponin I And T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein, Other Cardiac Biomarkers
3) By Application: Laboratory Testing Facilities, Point-Of-Care Testing Facilities, Academic Institutions
Subsegments:
1) By Reagents and Kits: Troponin Test Kits, B-type Natriuretic Peptide (BNP) Test Kits, Creatine Kinase-MB (CK-MB) Test Kits, Myoglobin Test Kits, Other Cardiac Biomarker Reagents
2) By Instruments: Point-of-Care Testing Devices, Automated Analyzers, Immunoassay Systems, Portable Diagnostic Devices
Pre-Book The Cardiac Marker Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Cardiac Marker Testing Market?
Prominent firms engaged in the cardiac marker testing market are investing their resources in creating state-of-the-art products like cardiac assays. These are devised to deliver important, accurate details about cardiovascular well-being. Cardiac assays gauge biomarkers in the blood and other specimens to analyze cardiac activity, identify heart ailments, or calculate the probability of cardiac-related issues. For instance, in October 2023, Mindray, a major medical device firm based in China, introduced hs-cTnI and NT-proBNP cardiac biomarkers. The hs-cTnI assay boasts remarkable sensitivity, accuracy, and dependability, exceeding standard expectations by recording a 93% detection ratio between the limit of detection (LoD) and up to 99th percentile upper reference limit (URL), while keeping an imprecision coefficient of variation (CV) below 5% at 99th URL. This makes it extremely effective in identifying myocardial damage. Mindray's NT-proBNP assay, an essential cardiac indicator for heart failure, illustrates a high degree of precision with a CV of =5%. It also effectively reduces disruption from 55 prevalent heart ailment drugs, ensuring precise detection and control of heart failure.
Who Are the Key Players In The Cardiac Marker Testing Market?
Major companies operating in the cardiac marker testing market are:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Danaher Corporation
• Siemens Healthineers AG
• Becton Dickinson and Company
• Laboratory Corporation of America Holdings
• Quest Diagnostics Inc.
• Tosoh Corporation
• bioMérieux SA
• Sysmex Corporation
• Bio-Rad Laboratories Inc.
• Guangzhou Wondfo Biotech Co. Ltd.
• Randox laboratories Ltd.
• Getein Biotech Inc.
• Fujirebio Inc.
• Mayo Clinic Laboratories
• Kainos Medicine Inc.
• Alere Inc.
• Nano-Ditech Corporation
• 1Drop Diagnostics
What Are The Regional Insights Into The Cardiac Marker Testing Market?
North America was the largest region in the cardiac marker testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac marker testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
